ONTX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 Apr 2024 @ 16:00):

Stats
Today's Volume	1.25M
Average Volume	126 338
Market Cap	20.90M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $-0.230 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.040
ATR14	$0.0140 (1.42%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-13	Guerin Mark Patrick	Buy	8 666	Common Stock
2024-03-14	Guerin Mark Patrick	Sell	2 591	Common Stock
2024-03-13	Guerin Mark Patrick	Sell	8 666	Restricted Stock Units
2024-03-13	Fruchtman Steven M	Buy	23 111	Common Stock
2024-03-14	Fruchtman Steven M	Sell	8 727	Common Stock

INSIDER POWER
76.11
Last 95 transactions
Buy: 2 889 396 \| Sell: 191 603

Volume Correlation

Long: -0.03 (neutral)

Short: 0.45 (neutral)

Signal:(62.373) Neutral

Onconova Therapeutics Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Onconova Therapeutics Inc Correlation - Currency/Commodity

0.29
( neutral )

0.63
( weak )

0.00
( neutral )

-0.32
( neutral )

0.47
( neutral )

-0.57
( weak negative )

Onconova Therapeutics Inc Financials

Annual	2023
Revenue:	$226 000
Gross Profit:	$226.00B (100 000 000.00 %)
EPS:	$-0.900

Q4	2023
Revenue:	$56 000.00
Gross Profit:	$56 000.00 (100.00 %)
EPS:	$0

Q3	2023
Revenue:	$57 000.00
Gross Profit:	$52 000.00 (91.23 %)
EPS:	$-0.230

Q2	2023
Revenue:	$57 000.00
Gross Profit:	$53 000.00 (92.98 %)
EPS:	$-0.200

Financial Reports:

No articles found.

Onconova Therapeutics Inc

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.